LPIXEL Inc., a leader in image analysis and processing technology in life science and medical research, is pleased to announce that Mr. Sunao Manabe, CEO of DAIICHI SANKYO COMPANY,LIMITED, introduced LPIXEL’s AI diagnostic imaging support technology “EIRL” and AI-based anti-cancer drug discovery technology “IMACEL”at The 37th Annual Meeting of the Japanese Society of Toxicologic Pathology.
The “Phenotypic Screening” technology, is one of the “IMACEL” technologies, developed by LPIXEL is being used for the screening of the candidate compounds of anti-cancer drugs by Daiichi Sankyo Group.
EIRL is the collective name given to LPIXEL’s AI medical image diagnostic support technology. LPIXEL aims to provide solutions that enable a faster and more accurate diagnosis by implementing its unique algorithms to analyze medical big data, such as brain MRI, chest X-rays, and colonoscopy. For more information, please visit https://eirl.ai/en/
IMACEL is the AI image analysis and processing technology specialized in drug discovery with one-step support on study design, seeds findings, and evaluation of diseases.
Both Japan and global pharmaceutical companies tackled to utilise AI technology not only research fields but also others. AI technologies promise for the acceleration of drug discovery by surpassing the recognition and evaluation ability of mankind. Those AI technologies realize several tasks that are difficult for mankind; i.e. finding subtle differences, processing huge amounts of image data. LPIXEL accumulates AI technologies for accelerating drug discovery by co-developing with Astellas Pharma Inc, Takeda Pharmaceutical Company Limited. and more.For more information, please visit https://imacel.net
About Phenotypic Screening
Phenotypic Screening is an AI screening method based on cell morphology. In conventional approach, checking morphology of cells is too laborious to check all of them. Under limited conditions, conventional tests execute only 300~500 cells in one test. If you use our method, it is possible to recognize and categorize cells based on their morphology therefore it unlocked such laborious tasks and made it possible to find precise effects on the overall trend of cells and subtle differences of cells. By combination of conventional screening technology with our AI technology opens up finding novel drugs.
LPIXEL is a leader in advanced image analysis and processing technology encompassing the life science field. Founded in March 2014, LPIXEL is dedicated to offering research facilities, top-tier image analysis technologies and medical diagnosis technologies, both of which adopt advanced AI technology. LPIXEL revolves around business such as its medical image analysis software, “EIRL,” and its AI-based image analysis cloud service, “IMACEL.”
For more information, please visit https://lpixel.net/en/